Most Mounjaro coverage focuses on the dramatic early months — the initial weight loss, the adjustment to side effects, the excitement of a shrinking wardrobe. But what happens after a full year? Drawing on clinical data and real-world experiences from UK users, here is what the long-term picture looks like.
Weight Loss Trajectory
Clinical trial data from the SURMOUNT programme shows that weight loss on tirzepatide typically continues for 60–72 weeks before plateauing. At the one-year mark, participants on the highest dose (15mg) had lost an average of 22.5% of their body weight. Real-world results in the UK vary — factors like starting weight, dose, adherence, diet, and exercise all influence outcomes — but losses of 15–25% of body weight are commonly reported.
The plateau is not a failure. It represents a new equilibrium where energy intake and expenditure balance at a lower body weight. Some users find this difficult psychologically, having become accustomed to the scale dropping regularly.
Side Effects at One Year
The good news is that gastrointestinal side effects — nausea, vomiting, diarrhoea, constipation — typically improve significantly over time. Most long-term users report:
- Nausea is minimal or absent at a stable dose
- Appetite suppression continues but feels less dramatic than in the early months
- Energy levels have normalised
- Hair thinning (reported by some users in months 3–6) has generally resolved, with regrowth visible
Health Improvements
Beyond weight loss, one year on Mounjaro often brings measurable health gains:
- HbA1c reductions: Type 2 diabetes patients frequently achieve remission-level readings
- Blood pressure improvements: Many users have had antihypertensive medications reduced or stopped by their GP
- Improved cholesterol: Particularly reductions in triglycerides
- Mobility: Reduced joint pain, better mobility, and increased ability to exercise
- Sleep apnoea resolution: Some users no longer require CPAP therapy
The Psychological Journey
Long-term users often describe a complex emotional landscape. Initial euphoria gives way to a more measured experience. Common reflections include:
- Gratitude for the health improvements and quality-of-life gains
- Anxiety about what happens if the medication is discontinued
- Frustration with the ongoing cost (private prescriptions in the UK range from £150–£250 per month depending on the provider and dose)
- Coming to terms with Mounjaro as a long-term or potentially lifelong medication, similar to statins or blood pressure tablets
The Question of Continuation
One of the biggest decisions long-term users face is whether to continue indefinitely. Current evidence suggests that discontinuing tirzepatide leads to weight regain in most people — the SURMOUNT-4 trial showed participants regained approximately two-thirds of lost weight within a year of stopping. This does not mean the weight loss was pointless; the health benefits accrued during that time are real. But it does support the case for long-term treatment in many patients.
Advice from Long-Term Users
UK users who have been on Mounjaro for 12 months or more consistently share similar advice:
- Build healthy habits early — they are your safety net
- Do not compare your journey to others
- Maintain regular check-ups with your prescriber
- Accept that this is a marathon, not a sprint
One year on Mounjaro is not the end of the story. For many, it is the beginning of a healthier chapter — one that requires ongoing commitment, medical support, and self-compassion.